Evidence map›Paper›PMID 29416747›Full record

ArticleOncotarget2018

CD34

Willie Lin, Yogi Chang-Yo Hsuan, Yu-Chin Su, Cheng-Hsien Lin, Mao-Tsun Lin, Zi-Hao Chen, Ching-Ping Chang, Kao-Chang Lin

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Willie LinMeridigen Biotech Co., Ltd., Taipei, Taiwan.
Yogi Chang-Yo HsuanMeridigen Biotech Co., Ltd., Taipei, Taiwan.
Yu-Chin SuMeridigen Biotech Co., Ltd., Taipei, Taiwan.
Cheng-Hsien LinMeridigen Biotech Co., Ltd., Taipei, Taiwan.
Mao-Tsun LinDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Zi-Hao ChenInstitute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Ching-Ping ChangDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Kao-Chang LinDepartment of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
Chi Mei Medical Center · TWNational Cheng Kung University · TWSouthern Taiwan University of Science and Technology · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD34 is a transmembrane phosphoglycoprotein used to selectively enrich bone marrow in hematopoietic stem cells for transplantation. Treating rats with CD34

Indexed as

heat strokeinflammationischemiamesenchymal stem cellsplacenta

Identifiers

PMID29416747
PMCPMC5788615
OpenAlexW2774055861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.